Abstracts tagged "denosumab"

Abstract Number: 917 • 2014 ACR/ARHP Annual Meeting
Evaluation of Invasive Oral Procedures and Events in Women with Postmenopausal Osteoporosis Treated with Denosumab: Results from the Pivotal Phase 3 Fracture Study Extension
Nelson B. Watts¹, John T. Grbic², Michael McClung³, Socrates Papapoulos⁴, David Kendler⁵, Christence S. Teglbjaerg⁶, Lawrence O'Connor⁷, Rachel B. Wagman⁷, Eric Ng⁷, Nadia S. Daizadeh⁷ and Pei-Ran Ho⁷, ¹Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH, ²Columbia University, New York, NY, ³Oregon Osteoporosis Center, Portland, OR, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶Center for Clinical and Basic Research, Ballerup, Denmark, ⁷Amgen Inc., Thousand Oaks, CA
Background/Purpose: Osteonecrosis of the jaw (ONJ) is a rare but serious adverse event of some antiresorptive therapies, including denosumab (DMAb), and invasive oral procedures and…
Abstract Number: 2316 • 2014 ACR/ARHP Annual Meeting
Adherence to Denosumab in a Large Healthcare System
Robert A. Overman¹, Julie C. Lauffenburger², Margaret L. Gourlay³ and Chad L. Deal⁴, ¹Eshelman School of Pharmacy - Division of Pharmaceutical Policy and Outcomes, University of North Carolina, Chapel Hill, NC, ²Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, ³Family Medicine, University of North Carolina, Chapel Hill, NC, ⁴Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH
Background/Purpose: Oral bisphosphonates adherence has been reported as less than 50% at one year. Adherence to denosumab has been reported to be higher than alendronate…
Abstract Number: 2254 • 2014 ACR/ARHP Annual Meeting
Changes in Subject Characteristics in the Denosumab Pivotal Fracture Trial and Its Extension for up to 8 Years
JD Adachi¹, CJF Lin², PR Ho², MA Bolognese³, HG Bone⁴, P Hadji⁵, S Papapoulos⁶, C Recknor⁷, NS Daizadeh², P Dakin², RB Wagman² and S Ferrari⁸, ¹McMaster University, Hamilton, ON, Canada, ²Amgen Inc., Thousand Oaks, CA, ³Bethesda Health Research Center, Bethesda, MD, ⁴Michigan Bone and Mineral Clinic, Detroit, MI, ⁵Philipps-University of Marburg, Marburg, Germany, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷United Osteoporosis Centers, Gainesville, GA, ⁸Geneva University Hospital, Geneva, Switzerland
Background/Purpose: Changes in demographics of study population enrolled in long-term osteoporosis clinical trials may affect interpretation of efficacy/safety outcomes. Denosumab is being evaluated for up…
Abstract Number: 2264 • 2014 ACR/ARHP Annual Meeting
Denosumab for Long-Term Glucocorticoid Users Who Have Inadequate Response to the Bisphosphonates: A 12-Month Randomized Control Trial
Chi Chiu Mok¹, Ling Yin Ho¹ and Kwok Man Ma², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Nuclear Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose To evaluate the efficacy of denosumab on bone mineral density (BMD) in long-term glucocorticoid users who have inadequate response to oral bisphosphonate treatment.Methods Patients…
Abstract Number: 1890 • 2014 ACR/ARHP Annual Meeting
Consistent Inhibition of Bone Destruction By Denosumab in Important Subgroups of Japanese Patients with Rheumatoid Arthritis
Naoki Ishiguro¹, Yoshiya Tanaka², Hisashi Yamanaka³, Toshiyuki Yoneda⁴, Takeshi Ohira⁵, Naoki Okubo⁶, Harry K. Genant⁷, Desiree van der Heijde⁸ and Tsutomu Takeuchi⁹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ⁴Indiana University School of Medicine, Indianapolis, IN, ⁵Daiich Sankyo Co. Ltd, Tokyo, Japan, ⁶1-2-58, Hiromachi, Daiichi Sankyo Co. Ltd, Tokyo, Japan, ⁷University of California, San Francisco, CCBR-Synarc, Newark, Tiburon, CA, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose Denosumab is a fully human monoclonal antibody (IgG2 subclass) that binds specifically to RANKL, inhibits osteoclast-induced bone resorption by preventing the binding of RANKL…
Abstract Number: 1795 • 2014 ACR/ARHP Annual Meeting
Denosumab Restores Cortical Bone Loss at the Distal Radius Associated with Aging and Reduces Wrist Fracture Risk: Analyses from the Cross-over Group in the Extension of the Denosumab Pivotal Fracture Trial
JP Bilezikian¹, CL Benhamou², CJF Lin³, JP Brown⁴, NS Daizadeh³, PR Ebeling⁵, A Fahrleitner-Pammer⁶, E Franek⁷, N Gilchrist⁸, PD Miller⁹, JA Simon¹⁰, I Valter¹¹, CAF Zerbini¹² and C Libanati³, ¹College of Physicians and Surgeons, Columbia University, New York, NY, ²CHR d'Orléans, Orléans, France, ³Amgen Inc., Thousand Oaks, CA, ⁴CHU de Québec Research Centre and Laval University, Quebec City, QC, Canada, ⁵Monash University, Clayton, Australia, ⁶Medical University, Graz, Austria, ⁷Medical Research Center, Polish Academy of Sciences, Warsaw, Poland, ⁸The Princess Margaret Hospital, Christchurch, New Zealand, ⁹Colorado Center for Bone Research, Lakewood, CO, ¹⁰George Washington University, Washington, DC, ¹¹Center for Clinical and Basic Research, Tallinn, Estonia, ¹²Centro Paulista de Investigação Clinica, São Paulo, Brazil
Background/Purpose: Cortical bone loss is a major determinant of increased fracture risk. Denosumab (DMAb) has been shown to increase BMD at sites of cortical bone,…
Abstract Number: 2800 • 2013 ACR/ARHP Annual Meeting
Dose-Response Effects Of Denosumab, a Novel Subcutaneous RANKL Inhibitor, On The Progression Of Bone Erosion In Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate: Results Of Phase II DRIVE Study – A Twelve Month Placebo Controlled, Randomized, Double Blind Study
Tsutomu Takeuchi¹, Yoshiya Tanaka², Naoki Ishiguro³, Hisashi Yamanaka⁴, Toshiyuki Yoneda⁵, Harry K. Genant⁶ and Désirée van der Heijde⁷, ¹Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Institute of Rheumatology Tokyo Women's Medical University, Tokyo, Japan, ⁵Indiana University School of Medicine, Indianapolis, IN, ⁶University of California, San Francisco, CCBR-Synarc, Newark, Tiburon, CA, ⁷Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Denosumab is a fully human monoclonal antibody (IgG2 subclass) that binds specifically to RANKL. It inhibits osteoclast-induced bone resorption by preventing the binding of…
Abstract Number: 1384 • 2013 ACR/ARHP Annual Meeting
Estimation Of The Effect Of Denosumab On Bone Loss From The Results Of The 12-Month Phase II Study In Patients With Rheumatoid Arthritis (RA) On Background Methotrexate (MTX)
Yoshiya Tanaka¹, Tsutomu Takeuchi², Naoki Ishiguro³, Hisashi Yamanaka⁴, Toshiyuki Yoneda⁵, Harry K. Genant⁶ and Désiréé van der Heijde⁷, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Keio University, Tokyo, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Indiana University School of Medicine, Indianapolis, IN, ⁶University of California, San Francisco, CCBR-Synarc, Newark, Tiburon, CA, ⁷Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: RANKL is an essential factor for osteoclast differentiation and activation. Denosumab, a fully human monoclonal IgG2 antibody, is a potent inhibitor of RANKL and…
Abstract Number: 1237 • 2013 ACR/ARHP Annual Meeting
Denosumab Leads To Significantly Greater Increases In Bone Mineral Density Than Ibandronate and Risedronate In Postmenopausal Women At High Risk For Fracture Who Were Previously Treated With An Oral Bisphosphonate
Jacques P. Brown¹, Michael A. Bolognese², Pei-Ran Ho³, Jesse Hall³, Christian Roux⁴, Henry G. Bone⁵, Sydney Bonnick⁶, Joop van den Bergh⁷, Irene Ferreira⁸, Prayashi Ghelani⁹, Paula Dakin³, Rachel B. Wagman³ and Chris Recknor¹⁰, ¹CHU de Québec Research Centre and Laval University, Quebec City, QC, Canada, ²Bethesda Health Research Center, Bethesda, MD, ³Amgen Inc., Thousand Oaks, CA, ⁴Paris Descartes University, Paris, France, ⁵Michigan Bone and Mineral Clinic, Detroit, MI, ⁶Clinical Research Center of North Texas, Denton, TX, ⁷VieCuri Medical Centre and Maastricht University, Venlo, Netherlands, ⁸Amgen Inc., Cambridge, United Kingdom, ⁹Ovatech Solutions, London, United Kingdom, ¹⁰United Osteoporosis Centers, Gainesville, GA
Denosumab Leads to Significantly Greater Increases in Bone Mineral Density Than Ibandronate and Risedronate in Postmenopausal Women at High Risk for Fracture Who Were Previously…
Abstract Number: 864 • 2013 ACR/ARHP Annual Meeting
Further Reduction In Nonvertebral Fracture Rate Is Observed Following 3 Years Of Denosumab Treatment: Results With Up To 7 Years In The Freedom Extension
Jonathan D. Adachi¹, Serge Ferrari², Carol Zapalowski³, Paul D. Miller⁴, Jean-Yves Reginster⁵, Ove Törring⁶, Nadia Daizadeh³, Andrea Wang³, Cynthia O'Malley⁷, Rachel B. Wagman³ and E. Michael Lewiecki⁸, ¹McMaster University, Hamilton, ON, Canada, ²Geneva University Hospital, Geneva, Switzerland, ³Amgen Inc., Thousand Oaks, CA, ⁴Colorado Center for Bone Research, Lakewood, CO, ⁵University of Liège, Liège, Belgium, ⁶Karolinska Institutet, Södersjukhuset, Stockholm, Sweden, ⁷Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ⁸New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM
Further Reduction in Nonvertebral Fracture Rate Is Observed Following 3 Years of Denosumab Treatment: Results With up to 7 Years in the FREEDOM ExtensionBackground/Purpose: Some…
Abstract Number: 491 • 2013 ACR/ARHP Annual Meeting
Infection Risk Among Patients Receiving Concurrent Denosumab and Biologic Or Non-Biologic DMARD Therapy: An Analysis Of The Consortium Of Rheumatology Researchers Of North America (CORRONA) Registry
Vance J. Bray¹, Adam W. Bagley², Sterling G. West³, Carol J. Etzel⁴, Joel M. Kremer⁵ and Jason R. Kolfenbach⁶, ¹Denver Arthritis Clinic, Denver, CO, ²Internal Medicine, University of Colorado School of Medicine, Aurora, CO, ³Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴Department of Epidemiology, UT MD Anderson, Houston, TX, ⁵Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁶Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: RANKL is a cytokine member of the tumor necrosis family that mediates osteoclastic bone resorption. Denosumab prevents RANKL from activating RANK on the cell…
Abstract Number: 1998 • 2012 ACR/ARHP Annual Meeting
Relationship Between Changes in Bone Mineral Density and Incidence of Fracture with 6 Years of Denosumab Treatment
Michael A. Bolognese¹, Paul D. Miller², Jean-Yves Reginster³, Nathalie Franchimont⁴, Gerolamo Bianchi⁵, Roland Chapurlat⁶, Federico G. Hawkins⁷, David L. Kendler⁸, Beatriz Oliveri⁹, Jose R. Zanchetta¹⁰, Nadia Daizadeh⁴, Andrea Wang⁴, Rachel B. Wagman⁴ and Socrates Papapoulos¹¹, ¹Bethesda Health Research Center, Bethesda, MD, ²University of Colorado Health Sciences Center and Colorado Center for Bone Research, Lakewood, CO, ³Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium, ⁴Amgen Inc., Thousand Oaks, CA, ⁵LELICOMAR - Div Reumatologia, Azienda Sanitaria Genovese, Genoa, Italy, ⁶Hôpital Edouard Herriot, Lyon, France, ⁷Hospital Universitario, Madrid, Spain, ⁸University of British Columbia, Vancouver, BC, Canada, ⁹Laboratorio Enfermedades Metabólicas Oseas, Hospital de Clínicas, INIGEM UBA-CONICET, Buenos Aires, Argentina, ¹⁰Instituto de Investigaciones Metabólicas and University of Salvador, Buenos Aires, Argentina, ¹¹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: During the first 3 years of denosumab treatment in FREEDOM, there were continued increases in bone mineral density (BMD) and a robust reduction in…
Abstract Number: 1976 • 2012 ACR/ARHP Annual Meeting
Treatment Satisfaction in Postmenopausal Women Previously Treated with Bisphosphonates Who Transitioned to Denosumab Vs Ibandronate Therapy in an Open-Label Study
Santiago Palacios¹, Giovanni Iolascon², Irene Agodoa³, Hema Viswanathan³, Prayashi Ghelani⁴, Irene Ferreira⁵, Cynthia O'Malley⁶, Rachel B. Wagman⁷ and Sydney Bonnick⁸, ¹Instituto Palacios, Madrid, Spain, ²Seconda Universita di Napoli, Naples, Italy, ³Amgen Inc, Thousand Oaks, CA, ⁴Ovatech Solutions, London, United Kingdom, ⁵Amgen Inc., Cambridge, United Kingdom, ⁶Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ⁷Amgen Inc., Thousand Oaks, CA, ⁸Clinical Research Center of North Texas, Denton, TX
Background/Purpose: Higher treatment satisfaction is associated with greater persistence with osteoporosis therapy in postmenopausal women (Barrett-Connor OI 2012). Greater satisfaction has been reported with subcutaneous…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].